First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.

Journal of Translational Medicine
Chrystelle BrignoneFrédéric Triebel

Abstract

IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC) receiving first-line paclitaxel weekly, 3 weeks out of 4. MBC patients were administered one dose of IMP321 s.c. every two weeks for a total of 24 weeks (12 injections). The repeated single doses were administered the day after chemotherapy at D2 and D16 of the 28-day cycles of paclitaxel (80 mg/m2 at D1, D8 and D15, for 6 cycles). Blood samples were taken 13 days after the sixth and the twelfth IMP321 injections to determine sustained APC, NK and memory CD8 T cell responses. Thirty MBC patients received IMP321 in three cohorts (doses: 0.25, 1.25 and 6.25 mg). IMP321 induced both a sustained increase in the number and activation of APC (monocytes and dendritic cells) and an increase in the percentage of NK and long-lived cytotoxic effector-memory CD8 T cells. Clinical benefit was observed for 90% of patients with only 3 progressors at 6 months. Also, the objective tumor response rate of 50% compared favorably to the 25% rate reported in the histor...Continue Reading

References

Nov 1, 1995·European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies·W HüblP M Bayer
Oct 20, 2000·American Journal of Clinical Oncology·A W TongJ Nemunaitis
Mar 10, 2001·Nature·P ChampagneG Pantaleo
Aug 14, 2001·European Journal of Immunology·C A Byrd-LeiferA Ding
Mar 23, 2004·Annual Review of Immunology·Federica SallustoAntonio Lanzavecchia
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William E CarsonBarbara L Andersen
May 3, 2005·Nature Reviews. Cancer·Richard A Lake, Bruce W S Robinson
May 12, 2005·Current Opinion in Immunology·Antonio Lanzavecchia, Federica Sallusto
Dec 21, 2005·The Journal of Experimental Medicine·Noelia CasaresGuido Kroemer
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chrystelle BrignoneFrédéric Triebel
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hua ZhongGalina V Shurin
Dec 22, 2007·Nature Reviews. Immunology·Laurence ZitvogelGuido Kroemer
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Feb 26, 2008·Cancer Immunology, Immunotherapy : CII·N A Sheikh, L A Jones
Jul 25, 2008·The Journal of Biological Chemistry·Shanta M ZimmerJames P Snyder
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chrystelle BrignoneFrédéric Triebel

❮ Previous
Next ❯

Citations

Oct 1, 2011·Cancer Immunology, Immunotherapy : CII·C PanisR Cecchini
Feb 8, 2013·Cancer Immunology, Immunotherapy : CII·Gang Chen, Leisha A Emens
Sep 12, 2015·Acta Oncologica·Xiaodong LiChangping Wu
Dec 21, 2012·Expert Review of Anticancer Therapy·Leisha A Emens
Mar 15, 2014·Expert Opinion on Biological Therapy·Sara TomeiDavide Bedognetti
Oct 2, 2012·Cancer Investigation·L FuksaH Hornychova
Nov 19, 2015·Molecular Oncology·Anna ŚledzińskaSergio A Quezada
Sep 22, 2015·Pharmacology & Therapeutics·Johan M van RooijenElisabeth G E de Vries
Oct 5, 2015·Cancer Treatment Reviews·Elly MarcqEvelien L J Smits
Apr 8, 2016·Cancer Treatment Reviews·Maria Vittoria DieciValentina Guarneri
Nov 17, 2015·Immunotherapy·Amer AssalXingxing Zang
Apr 29, 2015·Journal of Cellular Physiology·Dominik WolfAnna Maria Wolf
Apr 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L ApetohF Ghiringhelli
Jan 27, 2015·Current Opinion in Immunology·Daniel Sanghoon Shin, Antoni Ribas
Aug 1, 2015·Nature Reviews. Drug Discovery·Kathleen M MahoneyGordon J Freeman
May 13, 2015·Cancer Metastasis Reviews·Ding ZhangXiangdong Wang
Mar 10, 2015·Journal of Neuro-oncology·Jennifer E Kim, Michael Lim
Oct 3, 2008·Journal of Hematology & Oncology·David Chu, Janice Lu
Feb 14, 2015·Current Oncology Reports·Brenda Ernst, Karen S Anderson
Dec 24, 2014·Nature Reviews. Immunology·Linh T Nguyen, Pamela S Ohashi
May 7, 2016·BMC Medicine·Sofia FarkonaIvan M Blasutig
May 20, 2016·Annual Review of Pathology·Scott B Lovitch, Scott J Rodig
May 14, 2016·Clinical Pharmacology and Therapeutics·K A MarroneJ Naidoo
Aug 30, 2016·CA: a Cancer Journal for Clinicians·Fernanda G HerreraGeorge Coukos
Mar 24, 2017·Expert Opinion on Biological Therapy·Giulia BottaiLibero Santarpia
Mar 17, 2017·World Neurosurgery·Alice L HungMichael Lim
Apr 28, 2017·Expert Opinion on Biological Therapy·Mariela A Moreno AyalaMarianela Candolfi
Sep 2, 2016·Therapeutic Advances in Medical Oncology·Cristina MigaliGiuseppe Curigliano
Jan 1, 2011·Cancers·Jaheli Fuenmayor, Ramon F Montaño
Nov 2, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Kok
Jan 12, 2016·Therapeutic Advances in Medical Oncology·Gregory T WurzMichael W DeGregorio
May 2, 2018·JAMA Oncology·Kyle ChangEduardo Vilar
Oct 18, 2018·Immunotherapy·Dass S Vinay, Byoung S Kwon
Nov 28, 2017·ESMO Open·Cinzia SolinasLaurence Buisseret
Apr 14, 2019·Cancers·Ben WylieJason Waithman
Apr 17, 2019·Expert Opinion on Therapeutic Patents·Martin Perez-SantosIrma Herrera-Camacho
May 8, 2019·Cancers·Sebastian ChrétienTheodoros Foukakis
Jul 11, 2019·Expert Opinion on Therapeutic Patents·Martin Perez-SantosNemesio Villa-Ruano
Jul 31, 2019·Expert Opinion on Investigational Drugs·Alvaro H Ingles GarcesJames Larkin
Jun 13, 2015·The Oncologist·Gregory K Pennock, Laura Q M Chow
May 21, 2020·Nature Reviews. Immunology·Alex D WaldmanMichael J Lenardo

❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy test
ELISA
flow cytometry

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.